Keenova Therapeutics Plc Net Income per Employee (MNK), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Keenova Therapeutics Plc  (MNK)
 

Keenova Therapeutics Plc Net Income per Employee

MNK's Quarterly Results, Trends, Rankings, Statistics
Keenova Therapeutics Plc recorded a cumulative net loss of $-573 million during 12 month ending in the first quarter 2026.
The Healthcare sector has seen employees of 98 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 2733, from total ranking in previous quarter at 3019.


What is Income per Employee Ratio?






MNK Net Income per Employee (Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 26 2025)
III. Quarter
(Mar 28 2025)
I. Quarter
(Sep 27 2024)
III. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -358,188 -303,625 -242,688 -101,625 1,168,500
MNK's Total Ranking # 2733 # 3019 # 2958 # 2704 #
Seq. Net Income Change - - - - -


MNK Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 99
Healthcare Sector # 332
Overall Market # 2733

Net Income per Employee Statistics
High Average Low
$ 692,444 $ -192,430 $ -1,052,333
(Sep 27 2024)   (Sep 29 2023)







Companies with similar Income per Employee for 12 month ending Mar 31 2026, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2026Number of Employees Mar 31 2026


Date modified: 2026-08-29T17:14:29+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.